Clinical and pathological characteristics of cervical clear cell carcinoma in patients not exposed to diethylstilbestrol: a comprehensive analysis of 49 cases

Jing Zeng, Wei Jiang, Li Ke-min, Mengpei Zhang, Jinghong Chen, Yuanqiong Duan, Qingli Li, Rutie YinFrontiers in Oncology 2024 · DOI

This study, published in Frontiers in Oncology (July 2024), provides a detailed clinical and pathological profile of 49 patients with cervical clear cell carcinoma (CCCC) who were not exposed to diethylstilbestrol (DES) in utero. The findings suggest that for early-stage patients, fertility- and ovary-preserving surgeries are safe and effective, with survival outcomes primarily driven by traditional pathological risk factors like lymph node metastasis and stromal invasion.

TL;DR

This research analyzes one of the larger cohorts of "non-DES" cervical clear cell carcinoma, a rare malignancy often overshadowed by more common HPV-linked cancers. The study demonstrates that early-stage patients have a high 5-year survival rate (~88%) and can safely opt for fertility-preserving treatments, though advanced stages still carry significant risks.

What Problem Does This Paper Address?

Most cervical cancers are squamous cell carcinomas or adenocarcinomas strongly linked to high-risk Human Papillomavirus (HPV). Cervical clear cell carcinoma (CCCC) is a rare subtype, accounting for only 4–9% of cases. Historically, CCCC gained notoriety in the 1970s due to its link with in utero exposure to diethylstilbestrol (DES), a synthetic estrogen.

However, DES was banned decades ago, yet CCCC continues to appear in patients with no such exposure. Because it is so rare, there is a lack of consensus on its clinical behavior, its relationship with HPV, and whether aggressive radical surgeries are always necessary—especially for younger patients wishing to preserve fertility. This paper seeks to fill that knowledge gap by analyzing a decade's worth of cases from a major Chinese medical center.

Methods

The authors conducted a retrospective cohort study at the West China Second University Hospital, identifying 49 patients diagnosed with CCCC between 2011 and 2023.

  • Pathological Review: Two senior pathologists re-evaluated all specimens to ensure they met the WHO 2020 criteria for CCCC (identifying architectural patterns like solid, papillary, and tubulocystic structures).
  • Staging: All cases were re-staged according to the FIGO 2018 system for consistency.
  • Statistical Analysis: The team used Kaplan–Meier survival curves to estimate progression-free survival (PFS) and overall survival (OS). They employed Cox proportional-hazards models to identify which clinical variables (like tumor size or lymph node involvement) actually predicted patient outcomes.

Datasets

The study utilized a primary clinical dataset of 49 patients from the West China Second University Hospital of Sichuan University. While 52 patients were initially identified, three were excluded because their cancer had actually spread from the endometrium rather than originating in the cervix.

Key Insights and Ideas

  • The HPV Paradox: While most cervical cancers are HPV-dependent, the role of HPV in CCCC remains controversial. This study found that 39.6% of patients were HPV-positive. The authors discuss the "hit-and-run" theory: the virus might trigger the initial cellular alteration but then disappear, meaning the cancer no longer requires the virus to maintain its growth.
  • Bimodal Age Distribution: Unlike DES-linked CCCC, which usually hits women in their 20s, these cases showed a wider age range (10 to 71 years), with a median age of 48. This suggests the disease mechanism in non-DES patients is distinct.
  • Fertility is Feasible: Perhaps the most encouraging insight is that fertility-preserving surgery (like trachelectomy) and ovary-preserving surgery showed excellent results. Two patients in the study successfully gave birth post-treatment, and none of the patients who chose these options experienced recurrence during the follow-up period.
  • Prognostic Indicators: In univariate analysis, FIGO stage, pelvic lymph node (PLN) metastasis, lymphovascular space invasion (LVSI), and deep stromal invasion were all significant predictors of survival. However, in the multivariate analysis, no single factor remained statistically significant, likely due to the small sample size inherent in studying rare diseases.

Key Results

  • Survival Rates: The 5-year overall survival (OS) rate was 88.2%, and the 5-year progression-free survival (PFS) rate was 86.8%.
  • Clinical Presentation: The majority of patients (75.5%) were diagnosed at Stage I. The most common symptom was vaginal bleeding (73.5%).
  • Recurrence and Mortality: Six patients (12.2%) experienced recurrence, and five (10.2%) died during the median follow-up of 24.1 months.
  • Surgical Outcomes: 46 patients underwent surgery. Notably, the seven patients who underwent ovary-preserving surgery and the two who underwent fertility-preserving surgery remained disease-free.

Limitations and Future Work

The primary limitation is the retrospective nature of the study and the small sample size. While 49 cases is substantial for a rare cancer, it limits the power of multivariate statistical models to identify independent prognostic factors.

The authors suggest that future research should focus on:

  1. Multicenter prospective studies to validate these findings across different populations.
  2. Molecular sequencing to identify targeted therapies, specifically looking at mutations in genes like ARID1A and ATM, which have been implicated in clear cell malignancies.
  3. Immunotherapy exploration, as traditional chemotherapy and radiotherapy may not be the most effective tools for this specific histological subtype.

Summary updated

Abstract

Ovary-preserving treatment and fertility-preserving surgery are safe and feasible in early-stage CCCC. Surveillance other than adjuvant treatment may be a better choice for early-stage CCCC without any pathological risk factors. More targeted therapies and immunotherapy should be pursued in future studies.
BibTeX
@inproceedings{zeng2024clinical,
  author = {Jing Zeng and Wei Jiang and LI Ke-min and Mengpei Zhang and Jinghong Chen and Yuanqiong Duan and Qingli Li and Rutie Yin},
  title = {{Clinical and pathological characteristics of cervical clear cell carcinoma in patients not exposed to diethylstilbestrol: a comprehensive analysis of 49 cases}},
  booktitle = {Frontiers in Oncology},
  year = {2024},
  doi = {10.3389/fonc.2024.1430742},
}
Figure